As observed in the MTT assays, treatment with Herceptin alone did not show any decreased cell viability in MDA-MB-468 (HER-2/neu negative) breast cancer cells which confirms the specificity of Herceptin action. The gene discussed is ERBB2; the disease is breast carcinoma.